Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases ...
Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial ...
Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 10/12]IntroductionRecursion Pharmaceuticals (RXRX) is a ...
3don MSN
Recursion Pharmaceuticals (RXRX) stock is trending after hours: Here’s what you should know
Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...
Recursion Pharmaceuticals Inc. announced Thursday that Sanofi has selected the first development candidate under their research collaboration, triggering a $10 million milestone p ...
On Thursday, Recursion Pharmaceuticals ( RXRX) priced an offering of 61.54 million Class A shares at $3.25 each, expecting to raise approximately $200 million before expenses. The offering is expected ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results